These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1308 related articles for article (PubMed ID: 22986437)

  • 1. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
    Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
    Lacy BE; Schey R; Shiff SJ; Lavins BJ; Fox SM; Jia XD; Blakesley RE; Hao X; Cronin JA; Currie MG; Kurtz CB; Johnston JM; Lembo AJ
    PLoS One; 2015; 10(7):e0134349. PubMed ID: 26222318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome.
    Chapman RW; Stanghellini V; Geraint M; Halphen M
    Am J Gastroenterol; 2013 Sep; 108(9):1508-15. PubMed ID: 23835436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
    Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
    Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
    Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System.
    Chang L; Lacy BE; Moshiree B; Kassebaum A; Abel JL; Hanlon J; Bartolini W; Boinpally R; Bochenek W; Fox SM; Mallick M; Tripp K; Omniewski N; Shea E; Borgstein N
    Am J Gastroenterol; 2021 Sep; 116(9):1929-1937. PubMed ID: 34465695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
    Peng LH; Fang JY; Dai N; Shen XZ; Yang YL; Sun J; Yang YS
    J Dig Dis; 2022 Feb; 23(2):99-110. PubMed ID: 35019221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.